Login
Join
FOLLOW:
Subscribe Free
Magazine
eNewsletter
Checkout
Menu
Magazine
News
Manufacturing
Packaging
Development
Compliance
Top 20
Directory
Solution Center
Events
More
Magazine
News
Manufacturing
Packaging
Development
Compliance
Top 20
Directory
Solution Center
Events
Current / Back Issue
Features
Editorial
Columns
Digital Edition
eNewsletter Archive
Our Team
Editorial Guidelines
Subscribe Now
Advertise Now
Top Features
CEO Spotlight: Gaston Salinas
Single-use Fermenters for Microbial Biopharma Development & Manufacturing
Creating Solutions for CDMOs: An EPCMV Firm’s Perspective
The Transformative Potential of Gene Therapy
Parenteral Perspectives
Breaking News
Online Exclusives
Industry News
Collaborations & Alliances
Promotions & Moves
Trials & Filings
Financial Reports
Bio News & Views
Custom Sourcing News
Packaging & Tracking
CRO News
Live From Shows
Top News
Novartis 1Q Results
Kindeva Invests in Second Manufacturing Line for Greener Inhalers
Merck 1Q Results
PCI Pharma Services to Offer Facility Tours at BIO 2024
Abbvie 1Q Results
APIs
Aseptic Processing
Cleaning Validation
Clinical Trial Materials
Cytotoxics and High Potency Manufacturing
Equipment
Excipients
Extractables and Leachables
Facilities
Fill/Finish
Lyophilization
Parenterals
Process Development
Process Validation
Risk Management
Scale-up/ Technology Transfer
Solid Dosage/ Creams/ Ointments
Kindeva Invests in Second Manufacturing Line for Greener Inhalers
PCI Pharma Services to Offer Facility Tours at BIO 2024
Scorpius Holdings Expands Operations in San Antonio
Xcellbio, AmplifyBio Partner to Manufacture Solid Tumor-Targeting TCR-T Cell Therapy
Veranova, Phorum.AI Partner on Generative AI Chemistry Optimization
Capsules
Cold Chain Management
Injectables
Logistics
Serialization
Solid Dosage / Semi-solids
Supply Chain
Vials
Pharma Matters Q&A: PCI Pharma Services
Pharma Matters Q&A: Marken
Parenteral Perspectives
Pharma 4.0: CDMOs Digitalize to Enhance Customer Value
Clinical Trial Modernization - Optimizing the Supply of Decentralized Studies
Analytical Services
Bioanalytical Services
Bioassay Developement
Biologics, Proteins, Vaccines
Biosimilars
Chemistry
Clinical Trials
Drug Delivery
Drug Development
Drug Discovery
Formulation Development
Information Technology
Laboratory Testing
Methods Development
Microbiology
Preclinical Outsourcing
R&D
Toxicology
Beaconcure Partners with Phastar to Enhance Clinical Trial Review Processes
TFF Pharmaceuticals, Cleveland Clinic to Advance Multiple Influenza Vaccines
Duoning & Bioelectronica Partner to Commercialize Hypercell System
Advance Microbial Detection with Metagenomic Techniques
Siren Biotechnology, Catalent Partner for Manufacturing of AAV Gene Therapies
Filtration & Purification
GMPs/GCPs
Inspections
QA/QC
Regulatory Affairs
Validation
The Future of Pharmacovigilance is Proactive
Parenteral Perspectives
"3 Key Trends" with Rob Feltz
Cellares Launches Cell Q Automated cGMP QC Workcell for Cell Therapies
TATAA Biocenter Awarded GLP Accreditation
Companies
Categories
Corporate Capabilities
Add New Company
Contract Service Directory Companies
Abzena
BioTechnique
TaiMed Biologics
Solvias USA, LLC
August Bioservices
Companies
News Releases
Posters
Brochures
Services
Videos
Case Study
White Papers
Jobs
Contract Service Directory Companies
Abzena
BioTechnique
TaiMed Biologics
Solvias USA, LLC
August Bioservices
Webinars
Live From Shows
Magazine
Current / Back Issue
Features
Editorial
Columns
Editorial Guidelines
Subscribe Now
Advertise Now
Enewsletter Archive
Digital Edition
Directory
Companies
Categories
Corporate Capabilities
Add Your Company
Manufacturing
APIs
Aseptic Processing
Cleaning Validation
Clinical Trial Materials
Cytotoxics and High Potency Manufacturing
Equipment
Excipients
Extractables and Leachables
Facilities
Fill/Finish
Lyophilization
Parenterals
Process Development
Process Validation
Risk Management
Scale-up/ Technology Transfer
Solid Dosage/ Creams/ Ointments
cGMP Manufacture
Packaging
Capsules
Cold Chain Management
Injectables
Logistics
Serialization
Solid Dosage / Semi-solids
Supply Chain
Vials
Development
Analytical Services
Bioanalytical Services
Bioassay Developement
Biologics, Proteins, Vaccines
Biosimilars
Chemistry
Clinical Trials
Drug Delivery
Drug Development
Drug Discovery
Formulation Development
Information Technology
Laboratory Testing
Methods Development
Microbiology
Preclinical Outsourcing
R&D
Toxicology
Compliance
Filtration & Purification
GMPs/GCPs
Inspections
QA/QC
Regulatory Affairs
Validation
Top 20 Pharma & BioPharma
Contract Pharma Direct
Breaking News
Online Exclusives
Slideshows
Experts Opinions
Surveys
Outsourcing Survey
Salary Survey
Glossary
Videos
White Papers
Podcasts
Infographics
Microsites
Companies
News Releases
Posters
Brochures
Services
Videos
Case Study
White Papers
Contract Pharma Conference
Contract Pharma Conference
Speakers
Exhibitors
Conference Sessions
eBook
Webinars
Events
Industry Events
Live from Show Events
Webinars
Classifieds / Job Bank
Classifieds
Job Bank
About Us
About Us
Contact Us
Advertise With Us
Privacy Policy
Terms of Use
Search Results for '
novartis
'
Search For:
Refine by Dates:
From:
To:
Past 7 Days
|
Past 30 Days
Refine By Content:
All
Advanced Degrees
Ask The Board
Ask The Experts
Back Page
Bio News & Views
Blog
Breaking News
Business Corner
Buyers Guide Companies
Case Studies
Classifieds
Columns
Company Blog
Conference Sessions
Content Microsite
Ebook
Editorial
Executive Perspective
Expert's Opinion
FDA Watch
Features
Financial Analysis
Getting Results
Glossary
I Mak
India Report
Industry Events
Infographics
Jobs
Literature / Brochures
Live From Shows
Lowe Down
Managing Your Career
News Releases
Online Exclusives
Outsourcing Survey
Pharma Beat
Podcasts
Posters
Preclinical Outsourcing
Product Releases
Salary Survey
Services
Slideshows
Sponsored Content
Top 25 Pharma & BioPharma
Top Companies Report
Trials & Filings
Videos
Webinars
White Papers / Tech Papers
Contract Service Directory Companies
Solution Content Center Companies
Novartis Global Biotech Cooperations (CDMO)
View All Buyers Guide Companies »
Breaking News
|
Financial Reports
Novartis 1Q Results
Key growth drivers include Entresto with $1.9 billion in sales, up 34%, and Cosentyx with sales of $1.3 billion, up 23%.
05.20.24
Breaking News
|
Drug Development
|
Industry News
Novartis to Acquire Mariana Oncology for $1B Upfront
Gains a portfolio of radioligand therapies across a range of solid tumor indications.
05.03.24
Breaking News
|
Collaborations & Alliances
|
Drug Discovery
PeptiDream Expands Peptide Discovery Collaboration with Novartis
Will use its Peptide Discovery Platform System technology to identify and optimize novel macrocyclic peptides against targets selected by Novartis.
04.30.24
Breaking News
|
Collaborations & Alliances
|
Drug Development
Arvinas Enters Strategic License Agreement with Novartis for Novel Prostate Cancer Therapy
Novartis will be responsible for worldwide clinical development and commercialization of ARV-766.
04.11.24
Breaking News
|
Drug Development
|
Industry News
Novartis to Acquire IFM Due in Potential $835M Deal
Gains rights to IFM Due's portfolio of STING antagonists, which have the potential to treat an array of serious inflammation-driven diseases.
03.13.24
Bio News
|
Breaking News
|
Facilities
|
Industry News
Novartis Investing Roughly €500M in Biopharma Production in Austria
The expansion in cell culture technology will create 350 new jobs in Tyrol.
03.07.24
Breaking News
|
Drug Development
|
Industry News
Novartis to Acquire MorphoSys AG for €2.7B
To gain pelabresib and ruxolitinib combo, which offers potential for first line of treatment in myelofibrosis with regulatory filing planned 2H24.
02.06.24
Breaking News
|
Financial Reports
Novartis Revenues up 8% in the Quarter
Growth was mainly driven by Entresto, Kesimpta, Kisqali, Pluvicto and Scemblix.
02.01.24
APIs
IPP Announces Purchase of World-Class Grimsby, UK API Pharma Manufacturing Site from Novartis
Its subsidiary, Humber Industrials Ltd., has reached an agreement to purchase Novartis UK's 170-acre API manufacturing plant site and assets in Grimsby, UK.
Breaking News
|
Drug Development
|
Industry News
Novartis to Acquire Calypso Biotech
Gains rights to CALY-002, a therapeutic antibody with potential in dermatology, gastro-intestinal and rheumatology indications.
01.08.24
Breaking News
|
Clinical Trials
|
Collaborations & Alliances
|
Drug Development
|
Drug Discovery
|
Industry News
Novartis Acquires Chinese Biotech SanReno Therapeutics
Gains two late-stage assets targeting Immunoglobulin A Nephropathy (IgAN) with exclusive rights in greater China and Singapore.
01.05.24
Breaking News
|
Collaborations & Alliances
|
Drug Development
|
Drug Discovery
Voyager Therapeutics, Novartis Enter Strategic Capsid Collaboration
Novartis obtains target-exclusive access to Voyager’s TRACER capsids related to Huntington’s disease and spinal muscular atrophy.
01.02.24
Breaking News
|
Industry News
Novartis Issues Voluntary Recall of Sandimmune Oral Solution
Due to crystal formation observed in some bottles, which could potentially result in incorrect dosing.
11.27.23
Biologics, Proteins, Vaccines
|
Breaking News
|
cGMP Manufacture
|
Drug Development
|
Industry News
Novartis, Legend Biotech Enter Exclusive CAR-T Therapies Agreement
Aims to advance Legend’s autologous CAR-T cell therapy candidate, LB2102, using the Novartis T-Charge platform.
11.14.23
Breaking News
|
Drug Development
|
Promotions & Moves
Novartis Names Patrick Horber President International
Horber will drive next phase of international growth, and shape commercial strategy.
09.06.23
Breaking News
|
Collaborations & Alliances
|
Drug Development
Ionis, Novartis Partner on Next-Gen Program Targeting Lp(a) for CV Disease
Ionis' new and advanced technologies will be used to create next generation compound targeting Lp(a).
08.03.23
NOVARTIS
...
07.17.23
Breaking News
|
Drug Development
|
Industry News
Novartis to Acquire DTx Pharma for $500M Upfront
DTx Pharma's Fatty Acid Ligand Conjugated Oligonucleotide (FALCON) platform facilitates extra-hepatic delivery of siRNA therapeutics.
07.17.23
Breaking News
|
Drug Development
|
Trials & Filings
Novartis’s Leqvio Approved for Adults with Elevated LDL-C
Can now be used earlier in LDL-C treatment as an adjunct to diet and statin therapy for high-risk patients who have not had a CV event.
07.10.23
Biologics, Proteins, Vaccines
|
cGMP Manufacture
|
Drug Development
|
VideoBites
Videobite: Contract Pharma Sits Down with Christoph Buerki of Novartis GlobalBiotech Cooperations
Head of Finance Operations & Contract Manufacturing discusses the company's strategic end to end CDMO services and manufacturing technologies.
Videos
Breaking News
|
Drug Development
|
Industry News
Novartis to Acquire Chinook Therapeutics for $3.2B Upfront
Will gain two high-value, late-stage assets in development for IgA nephropathy (IgAN), a rare, progressive chronic kidney disease.
06.12.23
Biologics, Proteins, Vaccines
|
Breaking News
|
Clinical Trials
|
Industry News
Novartis Buys Avrobio Gene Therapy for $88 Million
Purchases stem cell gene therapy program for cystinosis.
05.31.23
APIs
|
Breaking News
|
cGMP Manufacture
|
Industry News
Sterling Pharma Completes Acquisition of Novartis API Mfg. Facility
Provides additional capacity for Sterling’s API manufacturing services, and the deal includes an on-going supply agreement.
01.10.23
Biologics, Proteins, Vaccines
|
Breaking News
|
cGMP Manufacture
|
Industry News
BioNTech Acquires Novartis Mfg. Site in Singapore for mRNA Production
Establishes regional manufacturing capacities to support pipeline of mRNA-based vaccines and therapeutics across Asia Pacific region.
11.14.22
Breaking News
|
Industry News
Novartis to Spin Off Sandoz Unit
Also implementing a restructuring program that involves eliminating as many as 8,000 jobs.
08.26.22
Breaking News
|
Drug Development
|
Industry News
Novartis Restructures
To integrate Pharmaceuticals and Oncology business units and create two separate commercial organizations.
04.04.22
Biologics, Proteins, Vaccines
|
Breaking News
|
cGMP Manufacture
|
Industry News
|
Scale-up/Technology Transfer
Novartis, Carisma Ink Mfg. Pact for HER 2 Targeted CAR-M Cell Therapy
Initial agreement covers reservation of Novartis' state-of-the-art cell and gene facility in Morris Plains, NJ.
03.11.22
APIs
|
Breaking News
|
Facilities
|
Industry News
Sterling Pharma Solutions Acquires Novartis Facility
The CDMO expands its global API manufacturing capabilities with the purchase of the site in Ringaskiddy, Ireland.
03.04.22
Collaborations & Alliances
Oxford Biomedica, Novartis Extend & Update Commercial Supply Pact
Regains the ability to license its LentiVector platform across all CAR-T targets.
12.13.21
Breaking News
|
Industry News
Novartis to Sell Roche Stake in $20.7B Transaction
Novartis will report a gain from the sale in income from associated companies of approximately $14 billion.
11.04.21
Novartis
...
07.16.21
Biologics, Proteins, Vaccines
|
Breaking News
|
cGMP Manufacture
|
Industry News
AGC Biologics to Acquire Novartis Facility in Longmont, CO
Significantly expands cell and gene therapy capabilities and offerings.
07.02.21
Breaking News
|
cGMP Manufacture
|
Industry News
|
Scale-up/Technology Transfer
CureVac, Novartis Ink COVID Vax Mfg. Pact
Novartis to manufacture the mRNA and bulk drug product of the CVnCoV vaccine for up to 50 million doses by the end of 2021.
Kristin Brooks
03.04.21
Breaking News
|
Formulation Development
|
Industry News
|
Promotions & Moves
Novartis Vet Joins CDMO Sai Life Sciences
Mahavir Prashad named as vice president of early phase process development.
Tim Wright, Editor, Contract Pharma
02.17.21
Aseptic Processing
|
Bio News
|
Biologics, Proteins, Vaccines
|
Breaking News
|
Collaborations & Alliances
|
Fill/Finish
|
Industry News
Novartis Inks Contract Manufacturing Deal for Pfizer-BioNTech COVID-19 Vaccine
Novartis to leverage manufacturing capacity and capabilities to address pandemic, supporting global supply of COVID-19 vaccine.
Tim Wright, Editor, Contract Pharma
01.29.21
Breaking News
|
Collaborations & Alliances
|
Industry News
|
Injectables
Novartis Invests in Credence MedSystems
Supporting ramp-up of manufacturing capacity for innovative injectable drug delivery systems.
Tim Wright, Editor, Contract Pharma
01.27.21
Financial Reports
Financial Report: Novartis
Pharmaceutical sales up 2% driven by Entresto, Cosentyx and Zolgensma.
Contract Pharma Staff
11.04.20
Bio News
|
Biologics, Proteins, Vaccines
|
Breaking News
|
Facilities
|
Industry News
Novartis Expands Kymriah Manufacturing Footprint
Gets green light for commercial CAR-T cell therapy manufacturing site in Asia.
Contract Pharma Staff
11.03.20
Biologics, Proteins, Vaccines
|
Breaking News
|
Collaborations & Alliances
REGENXBIO Achieves $80M Novartis Milestone
Zolgensma, which leverages REGENXBIO's NAV AAV9 vector, reaches $1 billion in sales.
Contract Pharma Staff
10.27.20
Breaking News
|
Collaborations & Alliances
Elsevier, Novartis Collaborate on Risk Assessment Prediction Tool
To develop a safety margin risk assessment prediction tool, largely using PharmaPendium data.
Contract Pharma Staff
10.22.20
Breaking News
|
Collaborations & Alliances
|
Facilities
|
Industry News
|
Parenterals
|
Solid Dosage/Creams/Ointments
Siegfried Acquires Two Pharma Manufacturing Sites from Novartis in Spain
Sites are specialized in the manufacturing of ophthalmic steriles as well as oral solid dosage forms and capsules used in inhalation devices.
Contract Pharma Staff
10.02.20
Breaking News
|
cGMP Manufacture
|
Industry News
BioNTech to Acquire Novartis Mfg. Site for COVID-19 Vax Production
Will accelerate BioNTech’s efforts to scale-up commercial manufacturing capacity for its mRNA COVID-19 vaccine candidate BNT162.
Contract Pharma Staff
09.17.20
Collaborations & Alliances
|
Drug Development
Sangamo, Novartis Partner to Develop Gene Therapies for Autism
Sangamo will receive $75M upfront and is eligible to receive up to $720M in potential milestones for three neurodevelopmental targets.
Contract Pharma Staff
07.30.20
Breaking News
|
Industry News
Novartis Launches Portfolio of Meds for COVID-19 Treatment
Portfolio of 15 generic and OTC medicines from Sandoz will be sold at zero-profit to governments in eligible countries during the pandemic.
Contract Pharma Staff
07.16.20
Novartis
...
Tim Wright, Editor, Contract Pharma
07.15.20
Breaking News
|
Collaborations & Alliances
|
Formulation Development
Vectura Earns $5M Novartis Milestone for Enerzair Breezhaler
Enerzair Breezhaler uses Vectura’s formulation IP, and is a first-in-class fixed-dose combination maintenance treatment for uncontrolled asthma.
Contract Pharma Staff
07.07.20
Breaking News
|
Industry News
Novartis Halts COVID-19 HCQ Study
Discontinues hydroxychloroquine clinical trial based on slow enrollment, no safety issues have been reported or efficacy conclusions made.
Contract Pharma Staff
06.22.20
Biologics, Proteins, Vaccines
|
Breaking News
|
Drug Development
|
Trials & Filings
Novartis’ Kymriah Gets RMAT Designation
Investigational new indication to treat patients with relapsed or refractory follicular lymphoma
Contract Pharma Staff
04.22.20
The Supply Chain House of Cards
The COVID-19 pandemic exposes pressures on extended global supply chains
Emil W. Ciurczak, DoraMaxx Consulting
04.01.20
Drug Delivery
CEO Spotlight: Will Downie
Vectura’s chief executive talks trends in the inhaled-drug market, and the company’s transition into a CDMO
Tim Wright, Editor, Contract Pharma
04.01.20
Breaking News
Novartis 1Q Results
Kindeva Invests in Second Manufacturing Line for Greener Inhalers
Merck 1Q Results
PCI Pharma Services to Offer Facility Tours at BIO 2024
Abbvie 1Q Results
View Breaking News >
CURRENT ISSUE
May 2024
CDMOs: The Cornerstone of Biopharmaceutical Innovation
Pharma 4.0: CDMOs Digitalize to Enhance Customer Value
CEO Spotlight: Gaston Salinas
Parenteral Perspectives
The Transformative Potential of Gene Therapy
Cell & Gene Therapy Outsourcing
Creating Solutions for CDMOs: An EPCMV Firm’s Perspective
Single-use Fermenters for Microbial Biopharma Development & Manufacturing
View More >